An unprecedented shift is occurring in the treatment of obesity and diabetes due to a new class of medications, glucagon-like peptide 1 (GLP-1) agonists, often referred to as GLP-1 agonists. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.